EGFR Mutant Lung Cancer: 2013 Update

preview_player
Показать описание
Lecia Sequist, MD, MPH
The presentation will review the state of the art in EGFR-mutant lung cancer.
  1. The AlphaMed Company, Inc.
  2. 3161449233001
  3. EFGR
  4. Lung Cancer
  5. mutant
  6. STO
Рекомендации по теме
EGFR Mutant Lung 0:45:43

EGFR Mutant Lung Cancer: 2013 Update

First-Line Therapy in 0:06:56

First-Line Therapy in the Patient with EGFR-Mutant Lung Cancer

EGFR mutation positive 0:23:10

EGFR mutation positive tumors: Treatment strategies in front line and at relapse

Acquired EGFR resistance: 0:20:07

Acquired EGFR resistance: What are the current therapeutic strategies?

TKI-resistant EGFR-mutant NSCLC 0:20:35

TKI-resistant EGFR-mutant NSCLC

Managing T790-negative EGFR-mutated 0:13:06

Managing T790-negative EGFR-mutated NSCLC

Individual Treatments for 0:17:45

Individual Treatments for Individual EGFR Mutations

Comment: Front-line osimertinib 0:01:36

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positi...

DEBATE: Drug of 0:16:22

DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Afatinib

Evolutions in the 0:02:02

Evolutions in the Treatment of EGFR-Mutated NSCLC

Are EGFR TKIs 0:01:02

Are EGFR TKIs (Such as Tarceva) Effective in Lung Cancer Patients Who Are Wild Type EGFR?

Beyond erlotinib: Are 0:21:41

Beyond erlotinib: Are second generation EGFR inhibitors better or simply newer?

Treatment Options for 0:24:36

Treatment Options for EGFR T790M Negative Acquired Resistance

Management of EGFR-Mutant 1:18:11

Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases

Frontline Afatinib in 0:04:09

Frontline Afatinib in EGFR-Mutant NSCLC

Managing progression in 0:19:53

Managing progression in EGFR-mutant NSCLC patients: Potential impact of 2nd and 3rd generation TKIs?

TATTON: Phase 1b 0:04:46

TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer

Debate: Adjuvant EGFR-directed 0:10:45

Debate: Adjuvant EGFR-directed therapy for patients with early stage NSCLC? - No

Treatment Options at 0:03:24

Treatment Options at Relapse for EGFR-Mutated NSCLC

Common Mutations in 0:05:58

Common Mutations in Lung Cancer

Debate: What is 0:10:06

Debate: What is the optimal timing for EGFR-targeted therapy? - Favor frontline therapy

Dr. Papadimitrakopoulou on 0:00:58

Dr. Papadimitrakopoulou on Treatment Options for EGFR-Mutant NSCLC

Debate: What is 0:10:05

Debate: What is the optimal timing for EGFR-targeted therapy? - Favor maintenance

Selecting a First-Line 0:06:46

Selecting a First-Line EGFR Inhibitor in NSCLC

visit shbcf.ru